The reduction of hepatic fibrosis by WAY-362450 treatment was paralleled by a reduction in hepatic gene expression of fibrosis markers and was specifically linked to the presence of FXR [32]. This evidence concerns the gene NR1H4 and Hepatic fibrosis.